| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
15002134094 |
| Email: |
marketing@targetmol.cn |
| Products Intro: |
Product Name:PF-7006
CAS:2771955-09-8
Package:50mg/RMB 27300
|
|
| | PF-7006 Basic information |
| Product Name: | PF-7006 | | Synonyms: | PF-7006;7H-Pyrrolo[2,3-d]pyrimidine-5-carbonitrile, 2-[[2-methyl-6-(4-morpholinyl)-3-pyridinyl]amino]-4-[(tetrahydro-2H-pyran-4-yl)amino]- | | CAS: | 2771955-09-8 | | MF: | C22H26N8O2 | | MW: | 434.5 | | EINECS: | | | Product Categories: | | | Mol File: | 2771955-09-8.mol |  |
| | PF-7006 Chemical Properties |
| density | 1.404±0.10 g/cm3(Temp: 25 °C; Press: 760 Torr)(predicted) | | pka | 11.015±0.50(predicted) |
| | PF-7006 Usage And Synthesis |
| Uses | PF-7006 is an Mps1 kinase inhibitor with a Ki value of 0.27 nM and an IC50 value of 2.5 nM. PF-7006 interferes with cell cycle checkpoints by inhibiting the catalytic activity of Mps1, reducing histone H3 levels, and shortening the duration of mitosis, leading to apoptosis in cancer cells. Combined use of PF-7006 with Palbociclib (HY-50767) increases cancer cell tolerance to PF-7006. PF-7006 can be used for breast cancer research[1]. | | References | [1] Martinez R, et al. Mitotic Checkpoint Kinase Mps1 Has a Role in Normal Physiology which Impacts Clinical Utility. PLoS One. 2015 Sep 23;10(9):e0138616. DOI:10.1371/journal.pone.0138616 |
| | PF-7006 Preparation Products And Raw materials |
|